
Wen Shen, MD, and Dana Sarnak, PhD, on MHT access and supply
Key Takeaways
- Rising MHT demand is straining access, with Shen’s nurses fielding 20 to 30 calls a day, especially for transdermal patches, and turning to gels and sprays when patches are unavailable while favoring transdermal estradiol.
- Sarnak said documenting these trends, including through a national-scale study, can help institutions and manufacturers forecast demand and prepare for shortages.
Wen Shen, MD, and Dana Sarnak, PhD, on MHT access strains at the pharmacy and the demand forecasting and equity research ahead.
The sharp rise in menopause hormone therapy (MHT) prescribing is
Building on their
Access and supply challenges at the pharmacy
Demand has created real access problems, Shen said, with her nurses fielding 20 to 30 phone calls a day from patients seeking hormone therapy, particularly transdermal patches, which she described as the most popular and a very safe form.
“My poor nurses are taking the brunt of this,” Shen said, describing staff calling local pharmacies, directing patients to national mail-order pharmacies, and using newer programs set up to provide access to name-brand hormone therapy.
When patches are unavailable, Shen said, her team turns to gels and sprays while still favoring transdermal estradiol and holding back on oral forms, though she noted that some oral options are effective and safe.
Forecasting demand and studying equity
Documenting these trends can help health systems and manufacturers anticipate demand, Sarnak said, noting that she is involved in a study examining the trends on a national scale.
By quantifying rising demand, particularly for specific formulations, institutions “can be better prepared and do better forecasting,” Sarnak said.
Future analyses will examine whether the increases are shared equitably across socioeconomic and geographic groups and will look at prescribing by specialty, she said.
For Shen, the trend fits a broader goal of healthy aging. Many women now live into their 80s but spend their final decades in poor health, she said, and better access to hormone therapy could help change that.
“I am very happy to see the movement that is happening,” Shen said, framing it as part of healthy aging in midlife and beyond.
References:
- Fitch J. FDA working with manufacturers to increase access to estradiol transdermal patches. Contemporary OB/GYN. Published September 4, 2026. Accessed November 19, 2026. https://www.contemporaryobgyn.net/view/fda-working-manufacturers-increase-estradiol-transdermal-patches
- The Menopause Society. Contemporary OB/GYN. Accessed November 19, 2026. https://www.contemporaryobgyn.net/conferences/nams
Related to this article








